OCAR Trademark

Trademark Overview

On Monday, April 5, 2021, a trademark application was filed for OCAR with the United States Patent and Trademark Office. The USPTO has given the OCAR trademark a serial number of 90624467. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Wednesday, July 17, 2024. This trademark is owned by ORNA THERAPEUTICS, INC.. The OCAR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of autoimmune, immune mediated, and inflammatory diseases and disorders, nucleic acid pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics for the treatment and prevention of autoimmune, immune mediated, and inflammatory diseases and disorders; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic vaccines; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Therapeutic pharmaceu...
ocar

General Information

Serial Number90624467
Word MarkOCAR
Filing DateMonday, April 5, 2021
Status734 - FIFTH EXTENSION - GRANTED
Status DateWednesday, July 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 7, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of autoimmune, immune mediated, and inflammatory diseases and disorders, nucleic acid pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics for the treatment and prevention of autoimmune, immune mediated, and inflammatory diseases and disorders; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical products for the prevention and treatment of cancer; Therapeutic vaccines; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Therapeutic pharmaceutical for the treatment of autoimmune, immune mediated, and inflammatory diseases and disorders, nucleic acid pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics for the treatment and prevention of autoimmune, immune mediated, and inflammatory diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, July 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameORNA THERAPEUTICS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
Party NameORNA THERAPEUTICS, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Thursday, April 8, 2021NEW APPLICATION ENTERED
Monday, July 12, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 21, 2021ASSIGNED TO EXAMINER
Monday, October 25, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 25, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 25, 2021NON-FINAL ACTION WRITTEN
Monday, October 25, 2021NON-FINAL ACTION E-MAILED
Monday, October 25, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 26, 2021NON-FINAL ACTION WRITTEN
Tuesday, October 26, 2021NON-FINAL ACTION E-MAILED
Tuesday, October 26, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 26, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 29, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 17, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 7, 2021PUBLISHED FOR OPPOSITION
Tuesday, December 7, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 1, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, August 1, 2022SOU EXTENSION 1 FILED
Monday, September 5, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 6, 2022TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 6, 2022PETITION TO REVIVE-GRANTED
Tuesday, September 6, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, September 6, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, September 7, 2022NOTICE OF REVIVAL - E-MAILED
Thursday, September 29, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 30, 2022SOU EXTENSION 1 GRANTED
Saturday, October 1, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 6, 2023ABANDONMENT - NO USE STATEMENT FILED
Monday, March 6, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, March 7, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, March 7, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 7, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, March 29, 2023PETITION TO REVIVE-GRANTED
Wednesday, February 1, 2023SOU EXTENSION 2 FILED
Tuesday, March 7, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 7, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 29, 2023TEAS PETITION TO REVIVE RECEIVED
Wednesday, March 29, 2023SOU EXTENSION RECEIVED WITH TEAS PETITION
Thursday, March 30, 2023NOTICE OF REVIVAL - E-MAILED
Thursday, March 30, 2023SOU EXTENSION 2 GRANTED
Friday, March 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 30, 2023ASSIGNED TO EXAMINER
Thursday, January 18, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 18, 2024SOU EXTENSION 4 FILED
Thursday, January 18, 2024SOU EXTENSION 4 GRANTED
Saturday, January 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 26, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, July 26, 2023SOU EXTENSION 3 FILED
Wednesday, July 26, 2023SOU EXTENSION 3 GRANTED
Wednesday, July 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 17, 2024SOU EXTENSION 5 FILED
Wednesday, July 17, 2024SOU EXTENSION 5 GRANTED

Related Keywords

ocar treatment pharmaceutical diseases disorders immune preparations prevention viral cancer system